Thursday, July 24, 2025 5:37:50 PM
So freaking tired of all the nonsense from both sides:
1. the thousands of 24/7 posts about how there is 0 chance of approval AND
2. the irrational AI generated posts claiming that a 500++ days and counting MAA review, under a 150/210 day expedited review process is somehow a great sign of a surprise expanded approval.
The FACT is that the only things we know for sure are:
1. that NWBO is diluting shareholders at pennies on the dollar over 100 MILLION shares a year and has far exceeded their authorized share count. (I would correct you that NWBO is selling new shares aka dilution NOT LP selling her own personal shares aka insider sales).
2. The MAA has neither been approved nor rejected for over 500 days and counting.
That’s it, no ASM, no NICE evidence submission, no updates for years, no proof of anything else. Praying for approval.
1. the thousands of 24/7 posts about how there is 0 chance of approval AND
2. the irrational AI generated posts claiming that a 500++ days and counting MAA review, under a 150/210 day expedited review process is somehow a great sign of a surprise expanded approval.
The FACT is that the only things we know for sure are:
1. that NWBO is diluting shareholders at pennies on the dollar over 100 MILLION shares a year and has far exceeded their authorized share count. (I would correct you that NWBO is selling new shares aka dilution NOT LP selling her own personal shares aka insider sales).
2. The MAA has neither been approved nor rejected for over 500 days and counting.
That’s it, no ASM, no NICE evidence submission, no updates for years, no proof of anything else. Praying for approval.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
